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Abstract
Background: Although efforts to improve the classification of hypersensitivity/allergic diseases have been made,
they have not been considered a top-level category in the International Classification of Diseases (ICD)-10 and still
are not in the ICD-11 beta phase linearization. ICD-10 is the most used classification system by the allergy
community worldwide but it is not considered as appropriate for clinical practice. The Systematized Nomenclature
of Medicine Clinical Terms (SNOMED CT) on the other hand contains a tightly integrated classification of
hypersensitivity/allergic disorders based on the EAACI/WAO nomenclature and the World Health Organization
(WHO) may plan to align ICD-11 with SNOMED CT so that they share a common ontological basis.
Methods: With the aim of actively supporting the ongoing ICD-11 revision and the optimal practice of Allergology,
we performed a careful comparison of ICD-10 and 11 beta phase linearization codes to identify gaps, areas of
regression in allergy coding and possibly reach solutions, in collaboration with committees in charge of the
ICD-11 revision.
Results: We have found a significant degree of misclassification of terms in the allergy-related hierarchies. This
stems not only from unclear definitions of these conditions but also the use of common names that falsely imply
allergy. The lack of understanding of the immune mechanisms underlying some of the conditions contributes to
the difficulty in classification.
Conclusions: More than providing data to support specific changes into the ongoing linearization, these results
highlight the need for either a new chapter entitled Hypersensitivity/Allergic Disorders as in SNOMED CT or a high
level structure in the Immunology chapter in order to make classification more appropriate and usable.
Keywords: Allergic diseases, Classification, International Classification of Diseases (ICD), Hypersensitivity diseases
Current status of the international classification of
diseases (icd) for allergic disorders
Background
The need for a classification of hypersensitivity/allergic
diseases
Allergic diseases can be expressed in many different or-
gans and in any age group, having a significant impact
on the quality of life of patients and their families. Every
health professional can face both mild and severe allergic
conditions and it is believed that the world is dealing
with a real allergy epidemic, resulting in considerable
consequences for patients around the world and in
important costs for societies [1]. The classification of
hypersensitivity/allergic diseases, supported by updated
knowledge of the underlying mechanisms, helps to
understand the ongoing scenario and to potentially assist
in the development of new diagnostic and management
approaches for these conditions.
During recent years, the allergy community has made
efforts to work on the classification of specific clinical
hypersensitivity/allergic diseases. These disorders repre-
sent what is commonly encountered in daily clinical
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practice and are included in regular continuous medical
educational programs in allergy meetings and congresses.
When searching for “classification of allergic diseases” in
PUBMED, the number of publications has tripled during
the last decade, regardless to the type/quality of the papers
(Figure 1). However, currently there is no universal stand-
ard platform in which allergic diseases are classified to
allow proper analysis of their impact in the medical com-
munity and the general population, allowing comparability
accepted worldwide.
Considering that without a common understanding and
a strict use of terms to define hypersensitivity/allergic
diseases, neither science nor patient care could be optimal,
the European Academy of Allergy and Clinical Im-
munology (EAACI) and the World Allergy Organization
(WAO) have joined forces to propose a revision of the
nomenclature for allergy for global use a few years ago [2]
but did not attempt at that time to liaise with the World
Health Organization (WHO) International Coding of
Diseases (ICD).
The WHO International Classification of Diseases
The International Classification of Diseases (ICD) is the
world’s standard tool to capture mortality and morbidity
data maintained by the World Health Organization
(WHO). This information is used to organize and code
health data that is used for statistics and epidemiology,
health care management, allocation of resources, moni-
toring and evaluation, research, primary care, prevention
and treatment. It attempts to provide a picture of the
general health situation of countries and populations as
well as standardize a common language for reporting and
monitoring diseases. The ICD is revised periodically and
the 11th revision is ongoing.
The ICD is the most used classification system by the
allergy community worldwide as demonstrated by the
recent EAACI–WAO survey on the global classification
and coding of hypersensitivity/allergic diseases [3], but it
was not considered appropriate for clinical practice by the
majority of participants. The majority of the responders in
this survey considered it neither easy nor accurate to
classify hypersensitivity/allergic diseases.
We have demonstrated that ICD-10 does not allow ac-
cess to reliable mortality data about some important aller-
gic conditions such as anaphylaxis [4]. If hypersensitivity/
allergic diseases are not adequately coded in ICD, this will
result in misclassification, leading to low visibility of
these conditions and therefore, inaccurate data capture.
The systematized nomenclature of medicine–clinical terms
The Systematized Nomenclature of Medicine Clinical
Terms (SNOMED CT) is an international reference ter-
minology with an ontological underpinning used for de-
cision support, outcomes analysis and interoperability. It
is derived from the merger of SNOMED RT (Reference
Terminology), a product of the college of American pa-
thologists and the Read codes, a product of the national
health service of the United Kingdom. In April 2007,
SNOMED-CT intellectual property rights were transferred
to the not-for-profit association International Health
Terminology Standards Development Organization (IHTSDO,
http://www.ihtsdo.org/).
Allergy terminology in SNOMED is based on the
EAACI-WAO nomenclature and is organized as an upper
level hierarchy under disease called hypersensitivity
condition, thus enabling the representation of hyper-
sensitivity propensities, processes (reactions) and diseases
for use in electronic health records [5].
Figure 1 Number of publications on “classification of allergic diseases” per year (1993-2014), according to a general search in the
PUBMED website.
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Although SNOMED CT is still not globally used and
the ICD-11 linearization structure remains under con-
struction, the WHO – IHTSDO joint advisory group
plans to align ICD-11 with SNOMED CT so that they
share a common ontological basis [6]. For this reason, it
would be advantageous to take the example of the repre-
sentation of hypersensitivity diseases in SNOMED CT to
improve allergological representation in the ICD-11.
The ICD-10 and the ICD-11 revision
Work on ICD-10 began in 1983 and was fully developed
by 1992 in order to track health statistics. ICD-10 is the
10th revision of the International Statistical Classification
of Diseases and Related Health Problems. It accounts for
more than 17,000 codes used by 25 countries for reim-
bursement and resource allocation in the health system
and by 110 countries for reporting cause of death report-
ing and statistics. The hypersensitivity/allergic diseases
are not considered as a separate category in ICD-10.
The 11th ICD was officially launched by WHO in
March 2007 and the final draft is expected to be submit-
ted to WHO’s World Heath Assembly for official en-
dorsement by 2017. Different from the ICD-10, which
was presented as just title headings, the proposed struc-
ture of ICD-11 includes definitions for each entity and
follows a content model.
We were able to highlight the “misclassification” of al-
lergic diseases in ICD-10 by the results of our commu-
nity survey [3]; however, when the beta phase of ICD-11
discussion was made available online in May 2012, the
linearization was pre-established by inheriting some ICD-
10 characters and developing some innovative aspects. A
proper classification/coding of hypersensitivity/allergic dis-
eases by clinical entity, by etiology or by symptom is still
missing in ICD-11 and incompletely classified by the ICD-
11 Topic Advisory Groups (TAGs) as of May 2014 [7].
Taking the above into account and with the aim of ac-
tive support of ICD-11 changes in favor of patients with
hypersensitivity/allergic diseases and improved practice
of Allergology and Clinical Immunology, we present a
careful comparison of ICD-10 (2010 version) and the
ICD-11 beta phase linearization codes (May 2014 ver-
sion) in order to identify any gaps and areas of regres-
sion in allergy coding and possibly achieve solution with
members of the ICD-11 TAGs.
Methods
Comparison between ICD-10 and ICD-11 beta phase
linearization for better coding of allergic diseases
The process of comparison
In the first phase of the process, we were able to prepare a
list of the important hypersensitivity/allergic diseases (key
words) that health care professionals are dealing with on a
daily basis. The EAACI-WAO revised nomenclature [2]
was the basis of the proposed categories, updated by new
knowledge generated since. It was, then validated by a
core group (LKT, MAC, PD) and cross-checked to avoid
overlapping terms and words able to provide dubious in-
terpretation of data. “Hypersensitivity” is defined as “con-
ditions clinically resembling allergy that cause objectively
reproducible symptoms or signs, initiated by exposure to a
defined stimulus at a dose tolerated by normal subjects”
and “allergy” as “a hypersensitivity reaction initiated by
immunologic mechanisms” [2]. However, these concepts can
generate some misunderstanding between non-specialists,
consequently the authors decided to always link the terms
hypersensitivity and allergy across the current paper. For
the purpose of the current paper this simplification is
used, however, the authors are aware that hypersensitivity
is not identical to allergy. In addition, notwithstanding the
importance of immunological diseases such as primary
and secondary immunodeficiencies and autoimmune
diseases, we did not include these conditions herein, as
they do not pose similar coding problems.
In the second phase of this project, to better construct
and appraise the proposed comparison between the ICD-
10 and the 11 beta phase on hypersensitivity/allergic
diseases, all possible and relevant corresponding codes
and classifications from the ICD-10 [8] and the ICD-11
beta phase linearization [7] were selected. All the process
of searching the key words correspondences from both
ICD-10 and 11-beta draft (May 2014 version) had an
online basis. With the aim of increasing the accuracy of
the search, an independent reviewer crosschecked all
codes. We are however aware that the definitive codifica-
tion is not established in the linearization up to now.
The preparation of the whole scheme containing all
the list of hypersensitivity/allergic diseases and corre-
sponding ICD-10 and 11 codes provided us a picture for
further evaluation. The document was extensively ana-
lyzed to go through the topics and have a real under-
standing of the innovations, map the gaps and trade-offs
and find the missing and/or imprecise terms of the ICD-
11 beta phase linearization as well as provide guidance
for the construction of a realistic global, cross-cultural,
multi-axial classification system useful for allergists,
non-allergists and non-physicians. Based on this analysis,
we were able to look for feasible solutions and suggest
changes to improve the positioning of allergic diseases
into the ongoing ICD-11 discussion.
Results and discussion
Lessons of the ICD comparison for hypersensitivity/
allergic diseases
Main hypersensitivity/allergic diseases categories
The outcome of the above process was the generation of
a list of 192 key words related to 10 main categories
of hypersensitivity/allergic diseases covering respiratory
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(asthma and rhinitis), skin (dermatitis, urticaria, angio-
edema), ocular (conjunctivitis) and complex and/or multi-
system diseases (drug, food and hymenoptera allergies and
anaphylaxis). Based on the analysis of these words into the
ICD-10 and 11 beta phase, we could identify the main
gaps and trade-offs.
Gaps related to hypersensitivity/allergic diseases in ICD-10
and ICD-11 beta
We noticed improvements in ICD-11 beta with regards
to hypersensitivity/allergic diseases; indeed, it was evi-
dent that several clinical patterns are scattered in many
different chapters across ICD-10 such as food and drug
hypersensitivity (Table 1). However, more than 3 differ-
ent clinical presentations (e.g., “anaphylactic shock non-
specified” and “angioneurotic oedema”) are still inappro-
priately classified under the same sub-chapter of ICD-11
beta (T78 of Chapter XIX Injury, poisoning and certain
other consequences of external causes), which is also not
considered by WHO rules as a valid underlying cause of
death, although it clearly is [4].
In terms of respiratory diseases, both asthma and rhinitis
were categorized in ICD-10 and ICD-11 beta basically by
time patterns (such as intermittent and persistent) and se-
verity (only for asthma) with no reference to the underlying
mechanisms. We also noticed the absence of important
etiologies as the content model of these classifications
concentrated in vague causative descriptions (“Allergic
rhinitis due to pollen”, “Other seasonal allergic rhinitis”
and “Other allergic rhinitis”), different from what is prop-
erly listed in SNOMED CT (Figure 2). In the May 2014
version of the ICD-11 beta draft, some aspects such as
exercise-exacerbated conditions, overlapping conditions
(e.g., Asthma induced by Aspirin and Exercise-induced
anaphylaxis dependent on food) and an updated classifica-
tion for occupational rhinitis and asthma are still absent.
Meanwhile, for ocular allergy, the ICD-10 and ICD-11
beta codes/classification have focused in substance by site
(e.g., Disorders of the eyeball – anterior segment); refer-
ences to cause and underlining mechanisms are still
missing.
We observed improvements in the classification of
skin allergies in ICD-11 beta compared to ICD-10 (e.g.,
inclusion of a more detailed contact dermatitis and
atopic eczema classification), but some systemic condi-
tions such as drug-induced anaphylaxis are still scattered
Table 1 Gaps and/or misclassification of the main hypersensitivity/allergic disorders described on the EAACI–WAO
revised nomenclature of allergy scattered across the ICD-10 chapters and sub-chapters (version 2010)
Hypersensitivity disorders
(according to the EAACI-WAO revised
nomenclature + updates)
ICD-10 version 2010 corresponding chapter(s) Main related sub-chapter(s)
according to the ICD-10
Asthma Chapter X: Diseases of the respiratory system J45.0 - J45.9, J46
Rhinitis Chapter X: Diseases of the respiratory system J30.0 – J30.4, J31, J33
Conjunctivitis Chapter VII Diseases of the eye and adnexa H10.0 – H10.9, H16.2 – H16.9, H18.6
Skin diseases Dermatitis Chapter XII Diseases of the skin and subcutaneous tissue L20 – L30
Urticaria Chapter XII Diseases of the skin and subcutaneous tissue L50.0 – L50.9
Angioedema Chapter XIX Injury, poisoning and certain other consequences
of external causes
T78.3
Chapter III Diseases of the blood and blood-forming organs and
certain disorders involving the immune mechanism
D84.1
Food hypersensitivity Chapter XIX Injury, poisoning and certain other consequences
of external causes
T78.0, T78.1
Chapter XII Diseases of the skin and subcutaneous tissue L23.6
Chapter XI Diseases of the digestive system K52.2, K52.3, K52.8, K52.9
Chapter XXI Factors influencing health status and contact
with health services
Z71.3
Drug hypersensitivity Chapter XIX Injury, poisoning and certain other consequences
of external causes
T88.1, T88.2, T88.6-T88.8
Chapter XX External causes of morbidity and mortality Y40.0 – Y59.9
Chapter XII Diseases of the skin and subcutaneous tissue L51 – L52
Chapter XXI Factors influencing health status and contact
with health services
Z88.0 – Z88.9
Venom hypersensitivity Chapter XX External causes of morbidity and mortality X23, X25, T63
Anaphylaxis Chapter XIX Injury, poisoning and certain other consequences
of external causes
T78.0 – T78.2
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into the chapter “Disorders of the Skin”. Although many
drug allergies may have a cutaneous clinical presenta-
tion, the drug hypersensitivity/allergic disorders can be
considered one of the most complex conditions once the
many factors involved in the pathogenesis are considered
[9], suggesting the need for a “Complex Hypersensitiv-
ity/Allergic Conditions” grouping. The “Diseases of the
Skin” chapter also incorporated the classification of in-
sect bite, venom or bite allergic reactions in the ICD-11
linearization. We noticed that the new classification pro-
posed was more detailed, trying to associate the clinical
presentation and the cause such as for allergic contact
dermatitis; however, systemic reactions were once again
lacking. In ICD-10, these allergic conditions were im-
properly classified under the Chapter XX External
causes of morbidity and mortality, sub-chapter “Contact
with venomous animals and plants”. The term “contact”
can allow multiple interpretations that can vary from a
direct cutaneous contact, such as an IgE-mediated con-
tact urticaria or a type IV contact dermatitis.
For anaphylaxis, the situation is not improved in ICD-
11 beta compared to ICD-10; indeed, in both classifica-
tions, anaphylaxis still resides under the same nonspecific
“Chapter XIX Injury, poisoning and certain other conse-
quences of external causes” which the main references
are “Anaphylactic shock due to adverse food reaction”
(T78.0) and “Anaphylactic shock, unspecified” (T78.2).
Anaphylaxis is defined as a “severe, life-threatening sys-
temic hypersensitivity reaction” [10], but we could iden-
tify some specific anaphylaxis conditions under the Skin
Disorders chapter, such as “anaphylaxis due to contrast
media” listed into the “Miscellaneous of urticarial disorders”
(Figure 3). Moreover, the term “shock”, which means the
drop of blood pressure, is one of the anaphylaxis manifes-
tations, however, should not be taken as synonymous or
always together. It suggests the need of implementing a
severity degree classification for anaphylaxis into the ICD.
Trade-offs identified by the ICD comparison for
hypersensitivity/allergic diseases
Knowledge generated since the EAACI-WAO revised
nomenclature publication [2] can be used to update out-
dated concepts and terms still present in the ICD-11
beta phase. An example of this is the term “vasomotor
allergic rhinitis” [11-13]. In the same way, the use of
some synonyms and narrow terms in the ongoing ICD-
11 beta revision may need update, such as the concepts
of intrinsic and extrinsic asthma, which has not been fa-
vored by the relevant medical communities, following
the understanding of asthma as a multi-phenotype dis-
ease [13-17]. Published classifications in specific areas of
the allergy field can support these changes [9-36]. For
that, the many allergy position papers and international
consensus should be considered [9-36].
Another trade-off in ICD-10 and ICD-11 is in the area
of drug allergy in which the mechanisms, clinical presen-
tations and causes are diluted within the ICD structure.
Clinical presentations remain scattered among many
chapters such as “Diseases of the Skin” and “External
Causes”; whereas drug allergy causes are still listed in
the “External Causes” chapter, under the “Complication
of Medical and Surgical Care” category and not linked to
the clinical presentation or related mechanism. The pre-
ceding may indicate the need for many different codes
to better characterize a reaction. This is a real weakness
of the ICD, preventing good statistics of one of the most
common drug side effects.
Conclusions
Outcomes of the ICD comparison for hypersensitivity/
allergic diseases
There is a significant degree of misclassification of terms
in the hypersensitivity/allergic - related hierarchies stem-
ming not only from unclear definitions of these condi-
tions but also from the use of common names that
falsely imply allergy, as well as a lack of understanding of
the immune mechanisms underlying some of the concepts
(Figure 3). Many of these issues have been corrected in
SNOMED CT, but an appropriate hypersensitivity/aller-
gic diseases classification is still missing in the (May 2014
version) ICD-11 structure.
We have highlighted the need for updating the hyper-
sensitivity and allergy conditions classification in the
ICD-11 beta revision by objectively examining evidences
of misclassification and missing and/or imprecise terms,
which may hamper the reliable documentation and
Figure 2 Upper level hierarchies representing hypersensitivity
and allergic disorders in SNOMED CT.
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analysis of allergy data worldwide. This scenario is par-
ticularly notable for some complex conditions, such as
drug allergy, food allergy and anaphylaxis requiring the
revision of the current structure of the ICD.
We believe that more than providing data to support spe-
cific changes into the ongoing linearization, these results
highlight the need for either a new chapter in ICD-11 pos-
sibly entitled Hypersensitivity/Allergic Disorders or at the
very least the aggregation of all such diseases under the
“Diseases of Immune System” chapter in order for the over-
laps to be double parented to the appropriate ‘system’ chap-
ters. Due to the previously mentioned major problems,
post-coordination with the existing codes will not be suffi-
cient. In this way, based on the discussions with some ac-
tive representatives of the groups in charge of the ICD-11
beta revision (Topic Advisory Groups) to have achieve-
ments to the Hypersensitivity/Allergic Diseases classifica-
tion into the ICD-11, they are aware that ICD-10 deals
poorly with allergy which does not fit neatly into a single
body system and has not been properly represented within
the revision process. In addition, representation by allergy
specialists in the ICD-11 revision process is still a lacking.
In conclusion, the data presented here aim to help fur-
ther discussion regarding the representation of allergy-
ICD-10 version 2010 ICD-11 Beta phase linearization
Chapter XIX Injury, poisoning and certain other consequences of external causes (S00-T98) 21 Injury, poisoning and certain other consequences of external causes 
Other and unspecified effects of external causes (T66-T78) Other and unspecified effects of external causes
T78Adverse effects, not elsewhere classified MD81 Adverse effects, not elsewhere classified
Parent
Other and unspecified effects of external causes
Definition 
Note:This category is to be used as the primary code to identify the effects, not elsewhere 
classifiable, of unknown, undetermined or ill-defined causes. For multiple coding purposes  
this category may be used as an additional code to identify the effects of conditions classified 
elsewhere.
Exclusion:
complications of surgical and medical care NEC (T80-T88)
T78.0 Anaphylactic shock due to adverse food reaction
T78.1 Other adverse food reactions, not elsewhere classified
Exclusions:
bacterial foodborne intoxications (A05.-)
dermatitis due to food (L27.2)
dermatitis due to food
T78.2 Anaphylactic shock, unspecified 
Allergic shock
Anaphylactic reaction
Anaphylaxis
Exclusions:
anaphylactic shock due to:
adverse effect of correct medicinal substance properly administered (T88.6)   
adverse food reaction (T78.0)
serum (T80.5)
Inclusions
Allergic shock NOS
Anaphylactic reaction NOS
Anaphylaxis NOS
Allergic reaction NOS
Hypersensitivity NOS
Idiosyncracy NOS
Exclusions
complications of surgical and medical care NEC
anaphylactic shock due to: adverse food reaction
anaphylactic shock due to: adverse effect of correct medicinal substance 
properly administered
anaphylactic shock due to: serum
specified types of allergic reaction such as: dermatitis
allergic reaction NOS to correct medicinal substance properly 
administered
specified types of allergic reaction such as: allergic gastroenteritis and 
colitis
specified types of allergic reaction such as: hay fever
T78.3 Angioneurotic oedema
Giant urticaria
Quincke oedema
Excl.:
urticaria (L50.-)
urticaria
T78.4 Allergy, unspecified
Allergic reaction NOS
Hypersensitivity NOS
Idiosyncrasy NOS
Exclusions:
allergic reaction NOS to correct medicinal substance properly administered (T88.7)
specified types of allergic reaction such as:
allergic gastroenteritis and colitis (K52.2)
dermatitis (L23-L25, L27.-)
hay fever (J30.1)
T78.8 Other adverse effects, not elsewhere classified
T78.9 Adverse effect, unspecified
Exclusions:
adverse effect of surgical and medical care NOS (T88.9) 
Disorders of the skin
Adverse cutaneous sequelae of medication and treatment 
Adverse cutaneous reactions to medication
EL72 Drug-induced urticaria, angioedema and 
anaphylaxis 
EL72.1 Drug-induced urticaria 
EL72.2 Drug-induced angioedema 
EL72.3 Drug-induced anaphylaxis 
EL72.Y Other specified drug-induced urticaria, 
angioedema and anaphylaxis 
EL72.Z Drug-induced urticaria, angioedema and anaphylaxis, unspecified
Figure 3 Examples of the inadequacy of the classification of anaphylaxis, drug and food allergy in ICD-10 and ICD-11 Beta phase linearization.
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related content in ICD-11 in order to improve the docu-
mentation and coding of this important domain of human
health. This document will help us to bring up the discus-
sion of the visibility of our specialty expecting for changes
and to support the recognition of allergy and clinical
immunology as a specialty by WHO. In addition, it may
serve as the basis of a classification proposal ready for
crowdsourcing the allergy community and to be shared
with WHO committees for future endorsement.
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